procarbazine has been researched along with Canine Diseases in 9 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 8.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 7.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle)." | 7.75 | Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. ( Childress, MO; Gieger, TL; Hume, KR; Keys, DA; Kosarek, CE; LeRoy, BE; Northrup, NC; Saba, CF; Wall, TM, 2009) |
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 4.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| "The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy." | 3.88 | LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. ( Brown, PM; Langova, V; Nguyen, S; Tzannes, S; White, J, 2018) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 3.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle)." | 3.75 | Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. ( Childress, MO; Gieger, TL; Hume, KR; Keys, DA; Kosarek, CE; LeRoy, BE; Northrup, NC; Saba, CF; Wall, TM, 2009) |
| "Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV." | 1.48 | Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. ( Amores-Fuster, I; Blackwood, L; Finotello, R; Harper, A; Killick, DR; Maddox, TW; Mason, SL; Tanis, JB, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blaxill, J | 1 |
| Buzzacott, P | 1 |
| Finlay, J | 1 |
| O'Connell, K | 2 |
| Thomson, M | 2 |
| Morgan, E | 2 |
| Henning, J | 1 |
| Zimmerman, K | 1 |
| Walsh, KA | 1 |
| Ferrari, JT | 1 |
| Keuler, NS | 1 |
| Atherton, MJ | 1 |
| Lenz, JA | 1 |
| Brown, PM | 1 |
| Tzannes, S | 1 |
| Nguyen, S | 1 |
| White, J | 1 |
| Langova, V | 1 |
| Tanis, JB | 1 |
| Mason, SL | 1 |
| Maddox, TW | 1 |
| Blackwood, L | 1 |
| Killick, DR | 1 |
| Amores-Fuster, I | 1 |
| Harper, A | 1 |
| Finotello, R | 1 |
| Griffin, A | 1 |
| Northrup, NC | 1 |
| Gieger, TL | 1 |
| Kosarek, CE | 1 |
| Saba, CF | 1 |
| LeRoy, BE | 1 |
| Wall, TM | 1 |
| Hume, KR | 1 |
| Childress, MO | 1 |
| Keys, DA | 1 |
| Rassnick, KM | 1 |
| Bailey, DB | 1 |
| Malone, EK | 1 |
| Intile, JL | 1 |
| Kiselow, MA | 1 |
| Flory, AB | 1 |
| Barlow, LL | 1 |
| Balkman, CE | 1 |
| Barnard, SM | 1 |
| Waite, AH | 1 |
| Fahey, CE | 1 |
| Milner, RJ | 1 |
| Barabas, K | 1 |
| Lurie, D | 1 |
| Kow, K | 1 |
| Parfitt, S | 1 |
| Lyles, S | 1 |
| Clemente, M | 1 |
1 trial available for procarbazine and Canine Diseases
| Article | Year |
|---|---|
Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Cyclophosphamide; Dog Diseases; | 2010 |
8 other studies available for procarbazine and Canine Diseases
| Article | Year |
|---|---|
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Hypercalcemia; Lomustin | 2022 |
Procarbazine, prednisolone and cyclophosphamide oral combination chemotherapy protocol for canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2022 |
Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Doxorubicin; Lymphoma; | 2023 |
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dog Diseases; Dogs; | 2018 |
Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2009 |
Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Drug Resistance, Neopla | 2011 |